DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fj7gd4/apoptosis_in) has announced the addition of the "Apoptosis in Oncology Drug Pipeline Update 2015" report to their offering.
Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells.
There are today 365 companies plus partners developing 406 apoptotic drugs in 2004 developmental projects in cancer. In addition, there are 9 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 255 drugs. Apoptosis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 335 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 325 out of the 327 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 67 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 48
- Registered - 1
- Pre-registration - 5
- Phase III - 74
- Phase II - 214
- Phase I - 208
- Preclinical - 172
- No Data - 16
- Suspended - 9
Ceased - 255
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/fj7gd4/apoptosis_in